Lab-grown lung cancer cells show potential to revolutionise treatment
The model could lead to more targeted treatments for the disease
Read MoreThe model could lead to more targeted treatments for the disease
Read Moreby Jen Brogan | Aug 8, 2024 | News | 0
Lung cancer accounts for an estimated two million global diagnoses and 1.8 million deaths
Read Moreby Jen Brogan | Jun 11, 2024 | News | 0
The leading cause of cancer globally accounts for an estimated 1.8 million deaths annually
Read Moreby Jen Brogan | Jun 3, 2024 | News | 0
The platform will be used to diagnose and treat cancers, including lung and brain tumours
Read Moreby Jen Brogan | May 22, 2024 | News | 0
Currently the third most common cancer in the UK, lung cancer affects 40,000 people annually
Read Moreby Jen Brogan | Apr 12, 2024 | News | 0
NSCLC is the most common type of lung cancer and is responsible for up to 85% of all cases
Read Moreby Jen Brogan | Apr 3, 2024 | News | 0
The third most common and serious form of cancer affects over 43,000 people every year in the UK
Read Moreby Jen Brogan | Mar 1, 2024 | News | 0
TMR-CT will help doctors select treatment and predict the spread of lung cancer in patients
Read Moreby Jen Brogan | Feb 13, 2024 | News | 0
The phase 1/2 Mobilize trial is evaluating the safety and efficacy of mRNA-4359
Read Moreby Jen Brogan | Jan 11, 2024 | News | 0
The diagnostic system can deliver particles to the lungs via aerosol or a nebuliser
Read Moreby Jen Brogan | Dec 18, 2023 | News | 0
Earlier diagnosis could increase patient survival rates by five years or more
Read Moreby Jen Brogan | Dec 7, 2023 | News | 0
The disease is one of the leading causes of cancer deaths in the UK
Read MorePharmaTimes Media Ltd.
Mansard House
Church Road
Little Bookham
Leatherhead
Surrey KT23 3JG
E: editorial@pharmatimes.com
E: subscriptions@pharmatimes.com
T: +44 (0)20 7240 6999
F: +44 (0)20 7240 4479